ALK and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: This review provides updated information gained from new cases of MiT family tRCC [1] and summarizes ALK-rearranged RCC, an emerging RCC subtype that may be treatable by ALK-targeted therapy.